News

At the Stem Cell Summit on 4/7, Sentien CEO Brian Miller announced that the company’s investigational new drug (IND) application for SBI-101 for the treatment of adult patients with acute [...]

Sentien Biotechnologies was featured on the front page of Medical Device Daily™ on April 7, 2017. In the article, Sentien CEO Brian Miller discusses the company’s recent $12M Series [...]

Sentien Biotechnologies CEO Brian Miller was featured on the front page of BioWorld™ Today on September 15, 2016.  Mr. Miller participated on a Biopharm America panel discussing “How [...]